NEW YORK – Telo Genomics said Friday it will collaborate with Mayo Clinic on clinical studies to evaluate and validate the company's proprietary telomere analytics as a prognostic solution for multiple myeloma.
The studies were designed to include two retrospective phases, with the potential of a third prospective phase. The first phase of the studies is expected to launch in the first quarter of 2020.